Detail Information of Post-Translational Modifications

General Information of Drug Transporter (DT)
DT ID	DTD0475 Transporter Info
Gene Name	SLC7A8
Transporter Name	L-type amino acid transporter 2
Gene ID	23428
UniProt ID	Q9UHI5

Post-Translational Modification of This DT
Overview of SLC7A8 Modification Sites with Functional and Structural Information
Sequence	M E E G A R H R N N T E K K H P G G G E S D A S P E A G S G G G G V A L K K E I G L V S A C G I I V G N I I G S G I F V S P K G V L E N A G S V G L A L I V W I V T G F I T V V G A L C Y A E L G V T I P K S G G D Y S Y V K D I F G G L A G F L R L W I A V L V I Y P T N Q A V I A L T F S N Y V L Q P L F P T C F P P E S G L R L L A A I C L L L L T W V N C S S V R W A T R V Q D I F T A G K L L A L A L I I I M G I V Q I C K G E Y F W L E P K N A F E N F Q E P D I G L V A L A F L Q G S F A Y G G W N F L N Y V T E E L V D P Y K N L P R A I F I S I P L V T F V Y V F A N V A Y V T A M S P Q E L L A S N A V A V T F G E K L L G V M A W I M P I S V A L S T F G G V N G S L F T S S R L F F A G A R E G H L P S V L A M I H V K R C T P I P A L L F T C I S T L L M L V T S D M Y T L I N Y V G F I N Y L F Y G V T V A G Q I V L R W K K P D I P R P I K I N L L F P I I Y L L F W A F L L V F S L W S E P V V C G I G L A I M L T G V P V Y F L G V Y W Q H K P K C F S D F I E L L T L V S Q K M C V V V Y P E V E R G S G T E E A N E D M E E Q Q Q P M Y Q P T P T K D K D V A G Q P Q P
PTM type	X-Phosphorylation X-Ubiquitination X: Amino Acid

Phosphorylation
Glycine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC7A8			[1]
Role of PTM	Potential impacts
Modified Residue	Glycine	Modified Location	51
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC7A8 Glycine 51 has the potential to affect its expression or activity.
Serine	4 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC7A8			[2] , [3]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	21
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC7A8 Serine 21 has the potential to affect its expression or activity.
PTM Phenomenon 2	Have the potential to influence SLC7A8			[3] , [4]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	24
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC7A8 Serine 24 has the potential to affect its expression or activity.
PTM Phenomenon 3	Have the potential to influence SLC7A8			[4] , [5]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	29
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC7A8 Serine 29 has the potential to affect its expression or activity.
PTM Phenomenon 4	Have the potential to influence SLC7A8			[1] , [3]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	502
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC7A8 Serine 502 has the potential to affect its expression or activity.
Threonine	3 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC7A8			[1] , [3]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	504
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC7A8 Threonine 504 has the potential to affect its expression or activity.
PTM Phenomenon 2	Have the potential to influence SLC7A8			[5] , [6]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	522
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC7A8 Threonine 522 has the potential to affect its expression or activity.
PTM Phenomenon 3	Have the potential to influence SLC7A8			[1] , [3]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	524
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC7A8 Threonine 524 has the potential to affect its expression or activity.
Tyrosine	2 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC7A8			[7]
Role of PTM	Potential impacts
Modified Residue	Tyrosine	Modified Location	214
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC7A8 Tyrosine 214 has the potential to affect its expression or activity.
PTM Phenomenon 2	Have the potential to influence SLC7A8			[3] , [8]
Role of PTM	Potential impacts
Modified Residue	Tyrosine	Modified Location	519
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC7A8 Tyrosine 519 has the potential to affect its expression or activity.
Valine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC7A8			[1]
Role of PTM	Potential impacts
Modified Residue	Valine	Modified Location	50
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC7A8 Valine 50 has the potential to affect its expression or activity.
Ubiquitination
Lysine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC7A8			[9]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	525
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC7A8 Lysine 525 has the potential to affect its expression or activity.

References
1	Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016 Jun 2;534(7605):55-62.
2	Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. Nat Commun. 2017 Mar 28;8:14864.
3	Identification of Missing Proteins in the Phosphoproteome of Kidney Cancer. J Proteome Res. 2017 Dec 1;16(12):4364-4373.
4	Specificity of Phosphorylation Responses to Mitogen Activated Protein (MAP) Kinase Pathway Inhibitors in Melanoma Cells. Mol Cell Proteomics. 2018 Apr;17(4):550-564.
5	Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors. Mol Syst Biol. 2018 Mar 5;14(3):e7858.
6	Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab. Neoplasia. 2018 Jul;20(7):668-677.
7	Glycoprotein capture and quantitative phosphoproteomics indicate coordinated regulation of cell migration upon lysophosphatidic acid stimulation. Mol Cell Proteomics. 2010 Nov;9(11):2337-53.
8	Feasibility of label-free phosphoproteomics and application to base-line signaling of colorectal cancer cell lines. J Proteomics. 2015 Sep 8;127(Pt B):247-58.
9	Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell. 2011 Oct 21;44(2):325-40.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.

Detail Information of Post-Translational Modifications

Visitor Map

Correspondence